Stock Evaluator: MBX Biosciences, Inc. (MBX)

MBX Biosciences, Inc. MBX

$53.41 -0.01 -0.02%
November 19, 2026 4:00:00 PM EST November 10, 2021 Volume: 748,194
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Commentary & Analysis


Financial Summary

Share Statistics MBX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $2,652.1 $403.8 59%
Shares Out (Mil) 48.6 47.2 47%
Institutional Ownership 96.7% 82.0% 70%
Float (Mil) 31.2 49.0 36%
Beta 0.18 0.68 11%
Avg Daily Volume (000s) 623 347 61%
Price Change
(52-week)
102.6% 51.1% 96%
Growth MBX Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 6.6% na
Net Income (5yr) na (1.4%) na
EPS (5yr) na 15.1% na
Dividends (5yr) na 0.0% na
Cash Flow (5yr) na (15.1%) na
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 7 7 8
Current EPS ($0.929) ($3.476) ($4.354)
Month Ago EPS ($0.931) ($3.054) ($3.976)
# Rev Up 0 0 0
# Rev Down 1 1 1
Three Months Ago EPS ($0.931) ($3.108) ($3.942)
Year/Year Chg (27.7%) 45.9% 128.1%
Financials MBX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $275 na
Net Income (TTM) (Mil) ($145) ($11) 8%
EPS (TTM) ($3.090) ($0.600) 11%
Operating Cash Flow (TTM) (Mil) ($96) ($7) 6%
Net Cash Flow (TTM) (Mil) ($61) $1 19%
Long-Term Debt (Q1) (Mil) $3 $4 21%
Enterprise Value (Q1) (Mil) $2,319 $373 51%
Valuation MBX Industry
Median
Percentile
(All Stocks)
P/B 5.60 2.20 84%
P/E na 21.1 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.1 na
Ratios MBX Industry
Median
Percentile
(All Stocks)
Gross Margin na 69.4% na
Net Margin na 3.5% na
ROA (32.2%) (24.6%) 15%
ROE (33.7%) (24.4%) 19%
Liabilities to Assets 5.5% 32.0% 3%
F-Score 1 3 1%

Passing Stock Screens

As of 11/19/2026, from a list of 60 stock screening strategies, MBX meetings the criteria of 2 screen:

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors